StockNews.com Begins Coverage on Aptose Biosciences (NASDAQ:APTO)

StockNews.com began coverage on shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) in a research note issued to investors on Wednesday. The brokerage issued a hold rating on the biotechnology company’s stock.

Separately, HC Wainwright reaffirmed a buy rating and set a $7.00 price objective on shares of Aptose Biosciences in a research report on Friday, June 14th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of Moderate Buy and a consensus target price of $9.00.

Aptose Biosciences Price Performance

Shares of NASDAQ APTO opened at $0.40 on Wednesday. Aptose Biosciences has a 52-week low of $0.33 and a 52-week high of $3.32. The business’s 50 day moving average is $0.48 and its two-hundred day moving average is $0.93. The firm has a market cap of $7.23 million, a price-to-earnings ratio of -0.06 and a beta of 1.25.

Aptose Biosciences (NASDAQ:APTO) (TSE:APS) last posted its quarterly earnings data on Thursday, August 8th. The biotechnology company reported ($0.43) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.58) by $0.15. Analysts anticipate that Aptose Biosciences will post -2.62 EPS for the current fiscal year.

Hedge Funds Weigh In On Aptose Biosciences

A hedge fund recently bought a new stake in Aptose Biosciences stock. Armistice Capital LLC acquired a new stake in Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 1,713,000 shares of the biotechnology company’s stock, valued at approximately $1,300,000. Armistice Capital LLC owned approximately 9.46% of Aptose Biosciences at the end of the most recent reporting period. 26.62% of the stock is currently owned by institutional investors.

About Aptose Biosciences

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.